Novartis AG’s DPP-4 inhibitor Galvus (vildagliptin), which has faced a deluge of alleged infringement attempts and patent-related challenges in India over the past few years, is now battling a multi-pronged legal attack by newest opponent Natco Pharma Ltd.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?